January 24, 2023
AmerisourceBergen will serve as Civica, Inc.’s exclusive distribution partner, providing supply chain support for Civica’s products and working to ensure that Civica’s crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.
January 31, 2023
“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”
February 8, 2023
Petersburg is at the center of a nonprofit’s push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city and expects to begin retail sales in 2024.

March 18, 2023
California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom, announcing the state’s choice of Civica to manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative. “We are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.”
April 11, 2023
CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.

April 20, 2023
The price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for The New England Journal of Medicine, titled “Falling Insulin Prices – What Just Happened?” One: The market is awaiting the entry of certain manufacturers that “don’t benefit from high prices.” Two: Government regulations are making it “costlier” for insulin manufacturers to keep charging their prior prices. Three: Public shaming.
May 3, 2023
Civica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support.

u003ch1u003eAmerisourceBergen Kicks Off Strategic Relationship with Civicau003c/h1u003enu003cp class=u0022body-contentu0022u003enAmerisourceBergen will serve as Civica, Inc.’s exclusive distribution partner, providing supply chain support for Civica’s products and working to ensure that Civica’s crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.u003c/pu003ennn
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003enu003ca href=u0022https://civicarx.org/wp-content/uploads/2023/01/Civica-AB-Partnership-Release_1.20.23.pdfu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eCivica Press Releaseu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eAmerisourceBergen Kicks Off Strategic Relationship with Civicau003c/divu003enn
u003culu003enu003ca href=u0022https://www.biospace.com/article/releases/amerisourcebergen-kicks-off-strategic-relationship-with-civica/u0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eBiospaceu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eAmerisourceBergen Kicks Off Strategic Relationship with Civicau003c/divu003e
u003ch1u003eCivica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiativeu003c/h1u003ennu003cp class=u0022body-contentu0022u003eu0022As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.u0022nu003c!u002du002du003cdiv class=u0022timeline-caption font-greenu0022 style=u0022padding-top: 10px;u0022u003e– Dan Liljenquist, u003cbr /u003eBoard Chair of Civica, and Chief Strategy Officer, u003cbr /u003eIntermountain Healthcare, and Martin VanTrieste, Civica CEO nu003c/divu003eu002du002du003eu003c/pu003e
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003enu003ca href=u0022https://civicarx.org/wp-content/uploads/2023/01/Ypsomed-Partnership-for-31-January-2023-FINAL.pdfu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eCivica Press Releaseu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCivica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiativeu003c/divu003enn
u003culu003enu003ca href=u0022https://www.contractpharma.com/contents/view_breaking-news/2023-02-07/civica-partners-with-ypsomed-for-insulin-injection-pen/u0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eContract Pharmau003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCivica Partners with Ypsomed for Insulin Injection Pennu003c/divu003e
u003ch1u003eUtah-based Nonprofit Set to Open $140M Insulin Plant in Petersburgu003c/h1u003enu003cp class=u0022body-contentu0022u003ePetersburg is at the center of a nonprofit’s push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city and expects to begin retail sales in 2024. u003c/pu003enn
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003enu003ca href=u0022https://www.axios.com/local/richmond/2023/02/08/petersburg-insulin-plant-nonprofit-pricesu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eAxios u003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eUtah-based Nonprofit Set to Open $140M Insulin Plant in Petersburgu003c/divu003enn
u003culu003enu003ca href=u0022https://www.youtube.com/watch?v=vaYGs1ZdIvsu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eVirtual Innovation Spotlight Webinar u003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eGame-changing Moves in Petersburg to Produce Affordable Insulin u003ciu003e(Please advance video to 12:00)u003c/iu003eu003c/divu003enn

u003ch1u003eCalifornia Selects Civica Rx as Its Insulin Manufacturing Partneru003c/h1u003ennu003cp class=u0022body-contentu0022u003eCalifornia’s partnership with Civica is a game changer,” said California Governor Gavin Newsom, announcing the state’s choice of Civica to manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative. “We are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.u0022nu003c/pu003en
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003enu003ca href=u0022https://www.civicainsulin.org/wp-content/uploads/2023/03/Civica-and-California-Partnership-PR-FINAL_.pdfu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eCivica Press Releaseu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCalifornia Selects Civica Rx as Its Insulin Manufacturing Partneru003c/divu003enn
u003culu003enu003ca href=u0022https://www.gov.ca.gov/2023/03/18/governor-newsom-announces-30-insulin-through-calrx/u0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eOffice of California Governor Gavin Newsomu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eGovernor Newsom Announces $30 Insulin Through CalRxu003c/divu003e
u003culu003enu003ca href=u0022https://www.wbur.org/npr/1164572757/california-contract-cheap-insulin-calrxu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eu003cliu003eWBURu003c/liu003eu003c/au003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCalifornia Enters a Contract to Make Its Own Affordable Insulinu003c/divu003e
nu003culu003en tu003cliu003eu003ca href=u0022https://www.fiercepharma.com/manufacturing/california-invests-50m-partner-civica-rx-insulin-manufacturingu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eFierce Pharmau003c/au003eu003c/liu003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCalifornia Invests $50M to Partner with Civica Rx on Insulin Manufacturingu003c/divu003en
u003ch1u003eCivicaScript, SortPak Partner to Package u0026 Deliver Medicines to Maximize Patient Convenience, Compliance u0026 Savingsu003c/h1u003enu003cp class=u0022body-contentu0022u003eCivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.u003c/pu003en
u003ch4u003eMedia Coverageu003c/h4u003e
nu003culu003en tu003cliu003eu003ca href=u0022https://civicarx.org/wp-content/uploads/2023/04/CivicaScript-SortPak-Final.pdfu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eCivica Press Releaseu003c/au003eu003c/liu003enu003c/ulu003ennu003cdiv class=u0022timeline-media-titleu0022u003eCivicaScript, SortPak Partner to Package u0026 Deliver Medicines to Maximize Patient Convenience, Compliance u0026 Savingsu003c/divu003e
u003culu003en tu003cliu003eu003ca href=u0022https://www.packagingconnections.com/news/civicascripttm-sortpak-partner-package-deliver-medicines-maximize-patient-convenienceu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003ePackaging Connectionsu003c/au003eu003c/liu003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCivicaScript, SortPak Partner to Package u0026 Deliver Medicinesu003c/divu003e

u003ch1u003eWhat Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Takeu003c/h1u003ennu003cp class=u0022body-contentu0022u003eThe price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for u003ciu003eThe New England Journal of Medicineu003c/iu003e, titled “Falling Insulin Prices – What Just Happened?” One: The market is awaiting the entry of certain manufacturers that “don’t benefit from high prices.” Two: Government regulations are making it “costlier” for insulin manufacturers to keep charging their prior prices. Three: Public shaming.u003c/pu003en
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003en tu003cliu003eu003ca href=u0022https://www.fiercepharma.com/pharma/impetus-behind-lilly-novo-and-sanofis-insulin-price-cuts-explained-reportu0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eFiercePharmau003c/au003eu003c/liu003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eWhat Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Takeu003c/divu003e
u003culu003en tu003cliu003eu003ca href=u0022https://www.nejm.org/doi/pdf/10.1056/NEJMp2303279u0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eNew England Journal of Medicineu003c/au003eu003c/liu003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eFalling Insulin Prices – What Just Happened?u003c/divu003e
u003ch1u003eCivicaRx Disrupts Out of Control Prescription Medication Pricingu003c/h1u003enu003cp class=u0022body-contentu0022u003eCivica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support. u003c/pu003en
u003ch4u003eMedia Coverageu003c/h4u003e
u003culu003en tu003cliu003eu003ca href=u0022https://techbuzz.news/civicarx/u0022 target=u0022_blanku0022 rel=u0022noopener noreferreru0022u003eTechBuzzu003c/au003eu003c/liu003enu003c/ulu003enu003cdiv class=u0022timeline-media-titleu0022u003eCivicaRx Disrupts Out of Control Prescription Medication Pricing Through Market Solutions Rather Than Government Regulationu003c/divu003e
